ProteoSys AG innovation in functional proteomics
home contact technology fee for
company publications cooperation
Current cooperations
Former cooperations
Former international cooperations

MiMage – Role of mitochondria in conserved mechanisms of ageing (FP6)

The overall aim of the MiMage project was to elaborate a more detailed view about the role of mitochondrial functions in ageing and lifespan control in biological systems. Of special interest was the discovery and experimental manipulation of evolutionarily conserved mechanisms shared between invertebrate and mammalian model systems.

Reprotect - Development of a novel approach in hazard and risk assessment or reproductive toxicity by a combination and application of in vitro, tissue and sensor technologies (FP6)

Reprotect, an Integrated Project with more than 30 European partners, intended to explore the most complicate and delicate field of toxicology, the reproductive toxicity. The investigation in this field currently requires substantial number of animals and the main objective of this IP was to reduce this number.

The project drove he R&D toward alternatives to animal tests according to the needs identified, with the main intention to pre-validate and validate the most promising ones. This represents the ambition of developing a novel approach in hazard and risk assessment of reproductive toxicity, by a combination and application of in vitro, tissue and sensor technologies.

Neupro-CF - Development of new methodologies for low abundance proteomics: application to cystic fibrosis (FP6)

Within the framework of Neupro-CF the molecules (proteins, lipids) which could represent the prognostic biomarkers of severity for cystic fibrosis were identified. In addition, the researchers developed a strategy based on the analysis in silico of mutated protein CFTR (produced from the gene of the same name) with experimental data to propose new corrective molecules. One of the project objectives was to study the molecular mechanisms which support the survival of the inflammatory cells, and in the medium-long term, to modulate their function and to limit their destroying potential.

Procure BioPharm - Prostate disorders: Procurement of Biomarkers & Pharmaceuticals (FP5)

New diagnostics, therapeutic substances and strategies were developed for prostate cancer (PCa). They have the potential to have a major socio-economic impact. PCa is debilitating, painful, incurable in its advanced stages, affects a large proportion of men, is increasing in frequency with the ageing population, and is a growing health-care cost burden. Proven performers from clinical, scientific and industrial backgrounds undertook goal-orientated research with development objectives. Human samples were used, to avoid the limitations of model systems. Novel technologies (DATAS, ProteoTope™) were exploited, developed by two SMEs (ExonHit and ProteoSys) and the latest advances in genomics to identify and validate alterations in genes and proteins in PCa. Selected alterations were used for the development of clinical markers and anticancer therapies. The achievements present great opportunities for scientific, technological and economic development.

Etablierung von In-vitro-Modellen zur Neuroprotektion mit molekularem Bezug zu menschlichen neurodegenerativen Erkrankungen (SET)
(Establishment of in vitro models for neuroprotection with molecular connotations to human neurodegenerative diseases)

The aim of this project was the characterisation of endpoints in mESC and hESC models for the quantification of neuroprotective effects of therapeutic compounds. Previous work with these models had so far aimed at a precise molecular and functional description of neurotoxic conditions (protein biomarker signatures for neuronal stress). Based on established protocols for neural differentiation in both models, various stages of neuronal maturation with regard to neurotransmitters, known marker proteins and pharmacologic properties were examined, and subsequently appropriately correlated endpoints for both species have been defined.

The project was funded by: SET - Stiftung zur Förderung der Erforschung von Ersatz- und Ergänzungsmethoden zur Einschränkung von Tierversuchen (Foundation for the Promotion of Alternate and Complementary Methods to Reduce Animal Testing)

 • MiMage

 • Reprotect

 • Neupro-CF

 • ProCure BioPharm

 • SET - in vitro models for neuroprotection